Renal Concerns in the Treatment of Chronic Hepatitis B with Tenofovir
Abstract
Tenofovir, a third generation oral nucleos(t)ide analogue, currently represents one of the first-line drugs recommended for treating chronic hepatitis B virus (HBV) infection. After oral administration, tenofovir is mostly excreted in the urine by glomerular filtration and proximal tubular secretion. Hence, an impaired kidney function may lead to an increased renal exposure to the drug in patients with coexistent renal damage. This could further worsen kidney disease through different mechanisms of nephrotoxicity such as mitochondrial DNA depletion and tubular cytotoxicity. Despite several studies performed so far to assess tenofovir-related renal toxicity, data in HBV patients are not yet conclusive. Screening of risk factors for kidney disease before starting therapy and a careful monitoring of serum creatinine, glomerular filtration rate, serum phosphate and urine analysis during treatment are advocated to adjust the dose or stop treatment if needed. New biomarkers of tubular injury, such as neutrophil gelatinase associated lipocalin, could become helpful in the future for the timely identification and risk stratification of renal damage induced by tenofovir.
Keywords
How to Cite
References
Maddrey WC. Hepatitis B: An important public health issue. J Med Virol. 2000;61(3):362–6. http://dx.doi.org/10.1002/1096-9071(200007)61:3%3C362::AID-JMV14%3E3.0.CO;2-I
European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85. http://dx.doi.org/10.1016/j.jhep.2012.02.010
Chen DS, Locarnini S, Wait S, Bae SH, Chen PJ, Fung JY, et al. Report from a Viral Hepatitis Policy Forum on implementing the WHO framework for global action on viral hepatitis in North Asia. J Hepatol. 2013;59(5):1073–80. http://dx.doi.org/10.1016/j.jhep.2013.06.029
Kang L, Pan J, Wu J, Hu J, Sun Q, Tang J. Anti-HBV drugs: Progress, unmet needs, and new hope. Viruses. 2015;7(9):4960–77. http://dx.doi.org/10.3390/v7092854
Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis. 2003;37(7):944–50. http://dx.doi.org/10.1086/378068
Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art. Antiviral Res. 2009;82(2):A84–98. http://dx.doi.org/10.1016/j.antiviral.2009.01.005
Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Nino MD, Izquierdo MC, Poveda J, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908. http://dx.doi.org/10.1155/2011/354908
Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clin Pharmacokinet. 2006;45(11):1115–24. http://dx.doi.org/10.2165/00003088-200645110-00005
Cha A, Besignano-Long AR, Rothberger N, Shah B. Reversibility of renal dysfunction after discontinuation of tenofovir. J Am Pharm Assoc (2003). 2016;56(3):280–3. http://dx.doi.org/10.1016/j.japh.2016.02.013
Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46(3):716–23. http://dx.doi.org/10.1128/AAC.46.3.716-723.2002
Woodward CL, Hall AM, Williams IG, Madge S, Copas A, Nair D, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10(8):482–7. http://dx.doi.org/10.1111/j.1468-1293.2009.00716.x
Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D’Agati VD, Markowitz GS. Tenofovir nephrotoxicity: Acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78(11):1171–7. http://dx.doi.org/10.1038/ki.2010.318
Brennan A, Evans D, Maskew M, Naicker S, Ive P, Sanne I, et al. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011;25(13):1603–9. http://dx.doi.org/10.1097/QAD.0b013e32834957da
Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D study. J Infect Dis. 2013;207(9):1359–69. http://dx.doi.org/10.1093/infdis/jit043
Wikman P, Safont P, Del Palacio M, Moreno A, Moreno S, Casado JL. The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients. Nephrol Dial Transplant. 2013;28(8):2073–81. http://dx.doi.org/10.1093/ndt/gft210
Perazella MA. Tenofovir-induced kidney disease: An acquired renal tubular mitochondriopathy. Kidney Int. 2010;78(11):1060–3. http://dx.doi.org/10.1038/ki.2010.344
Uteng M, Mahl A, Beckmann N, Piaia A, Ledieu D, Dubost V, et al. Editor’s highlight: Comparative renal safety assessment of the hepatitis B drugs, adefovir, tenofovir, telbivudine and entecavir in rats. Toxicol Sci. 2017;155(1):283–97. http://dx.doi.org/10.1093/toxsci/kfw208
Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010;24(11):1667–78. http://dx.doi.org/10.1097/QAD.0b013e328339fe53
Ando M, Tsuchiya K, Nitta K. How to manage HIV-infected patients with chronic kidney disease in the HAART era. Clin Exp Nephrol. 2012;16(3):363–72. http://dx.doi.org/10.1007/s10157-012-0585-7
Pipili CL, Papatheodoridis GV, Cholongitas EC. Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int. 2013;84(5):880–5. http://dx.doi.org/10.1038/ki.2013.249
Karras A, Lafaurie M, Furco A, Bourgarit A, Droz D, Sereni D, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36(8):1070–3. http://dx.doi.org/10.1086/368314
Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146(4):980–8. http://dx.doi.org/10.1053/j.gastro.2013.12.028
Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10(8):941–6; quiz e68. http://dx.doi.org/10.1016/j.cgh.2012.04.008
Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, et al. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl. 2013;19(6):594–601. http://dx.doi.org/10.1002/lt.23628
Winston J, Deray G, Hawkins T, Szczech L, Wyatt C, Young B. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis. 2008;47(11):1449–57. http://dx.doi.org/10.1086/593099
Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49(5 Suppl): S185–95. http://dx.doi.org/10.1002/hep.22885
Duarte-Rojo A, Heathcote EJ. Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Therap Adv Gastroenterol. 2010;3(2):107–19. http://dx.doi.org/10.1177/1756283X09354562
Ha NB, Ku KC, Ha NB, Chaung KT, Trinh HN, Nguyen HA, et al. Renal function in chronic hepatitis B (CHB) patients treated with tenofovir dipivoxil fumarate (TDF) monotherapy – A matched case cohort study. J Clin Gastroenterol. 2015;49(10):873–7. http://dx.doi.org/10.1097/MCG.0000000000000325
Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology. 2012;143(3):619–28.e1. http://dx.doi.org/10.1053/j.gastro.2012.05.037
Bam RA, Yant SR, Cihlar T. Tenofovir alafenamide is not a substrate for renal organic anion transporters (OATs) and does not exhibit OAT-dependent cytotoxicity. Antivir Ther. 2014;19(7):687–92. http://dx.doi.org/10.3851/IMP2770
Bam RA, Birkus G, Babusis D, Cihlar T, Yant SR. Metabolism and antiretroviral activity of tenofovir alafenamide in CD4(+) T-cells and macrophages from demographically diverse donors. Antivir Ther. 2014;19(7):669–77. http://dx.doi.org/10.3851/IMP2767
Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: A randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67(1):52–8. http://dx.doi.org/10.1097/QAI.0000000000000225
Daude M, Rostaing L, Saune K, Lavayssiere L, Basse G, Esposito L, et al. Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation. 2011;91(8):916–20. http://dx.doi.org/10.1097/TP.0b013e3182100f59
Yap DY, Chan TM. Evolution of hepatitis B management in kidney transplantation. World J Gastroenterol. 2014;20(2):468–74. http://dx.doi.org/10.3748/wjg.v20.i2.468
Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83. http://dx.doi.org/10.1002/hep.28156
Lampertico P, Chan HL, Janssen HL, Strasser SI, Schindler R, Berg T. Review article: Long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther. 2016;44(1):16–34. http://dx.doi.org/10.1111/apt.13659
Vigano M, Brocchieri A, Spinetti A, Zaltron S, Mangia G, Facchetti F, et al. Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. J Clin Virol. 2014;61(4):600–3. http://dx.doi.org/10.1016/j.jcv.2014.09.016
KDIGO CKD Working Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3:1–150.
Frequently asked questions about GFR estimates. https://www.kidney.org/sites/default/files/docs/12-10-4004_abe_faqs_aboutgfrrev1b_singleb.pdf [Accessed 17 Mar 2017].
Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis. 2008;52(3):595–605. http://dx.doi.org/10.1053/j.ajkd.2008.01.020
Cernaro V, Bolignano D, Donato V, Lacquaniti A, Buemi A, Crasci E, et al. NGAL is a precocious marker of therapeutic response. Curr Pharm Des. 2011;17(8):844–9. http://dx.doi.org/10.2174/138161211795428939
Strazzulla A, Coppolino G, Di Fatta C, Giancotti F, D’Onofrio G, Postorino MC, et al. Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection? World J Hepatol. 2016;8(19):815–24. http://dx.doi.org/10.4254/wjh.v8.i19.815
Campbell LJ, Dew T, Salota R, Cheserem E, Hamzah L, Ibrahim F, et al. Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients. BMC Nephrol. 2012;13:85. http://dx.doi.org/10.1186/1471-2369-13-85
Rasmussen TA, Jensen D, Tolstrup M, Nielsen US, Erlandsen EJ, Birn H, et al. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. PLoS One. 2012;7(3):e32445. http://dx.doi.org/10.1371/journal.pone.0032445
Allavena C, Bach-Ngohou K, Billaud E, Sécher S, Dejoie T, Reliquet V, et al. Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen. J Antimicrob Chemother. 2013;68(12):2866–70. http://dx.doi.org/10.1093/jac/dkt265
Oboho I, Abraham AG, Benning L, Anastos K, Sharma A, Young M, et al. Tenofovir use and urinary biomarkers among HIV-infected women in the Women’s Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr. 2013;62(4):388–95. http://dx.doi.org/10.1097/QAI.0b013e31828175c9
Copyright and licence
Copyright (c) 2017 Giuseppe Coppolino, Valeria Cernaro, Laura Rivoli, Angela Pinciaroli, Davide Bolignano
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
